Related content

Inhibition of p38 MAPK activity in B-NHL Raji cells by treatment with engineered CD20-specific T cells

By                    

Oncology Letters, Vol. 2, Iss. 4, 2011-01 ,pp. : 753-758

Spandidos Publications

Access to resources Recommend Favorite

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

By Smith Sonali M.  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1405-1410

Informa Healthcare

Access to resources Recommend Favorite

Anti-idiotype responses abrogate anti-CD4–induced tolerance to a tumor-specific antigen and promote systemic tumor immunity

By Kennedy Ronald   Shearer Michael   Lowe Devin   Jumper Cynthia   Chiriva-Internati Maurizio   Bright Robert  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 11, 2004-11 ,pp. : 987-994

Springer Publishing Company

Access to resources Recommend Favorite

Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-CELL chronic lymphocytic leukemia

By Cavalli-Björkman Nina   Ösby Eva   Lundin Jeanette   Kalin Mats   Österborg Anders   Gruber Astrid  

Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. : 277-280

Humana Press, Inc

Access to resources Recommend Favorite

Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo

By                    

Oncology Reports, Vol. 34, Iss. 5, 2015-01 ,pp. : 2567-2575

Spandidos Publications

Access to resources Recommend Favorite